Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Joyce O’Shaughnessy, Gursel Aktan et al.|New England Journal of Medicine|2020Cited by 3.1k
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by ageMartine Piccart, Emiel J. Rutgers, Laura van ‘t Veer et al.|The Lancet Oncology|2021Cited by 355
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesNader Hirmas, Wolfgang P. Fendler, Rainer Hamacher et al.|Journal of Nuclear Medicine|2022Cited by 68
Diagnostic Accuracy of<sup>68</sup>Ga-FAPI Versus<sup>18</sup>F-FDG PET in Patients with Various MalignanciesNader Hirmas, Wolfgang P. Fendler, Rainer Hamacher et al.|Journal of Nuclear Medicine|2024Cited by 31
Prognostic Implications of<sup>68</sup>Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid TumorsMasao Watanabe, Manuel Weber, Wolfgang P. Fendler et al.|Journal of Nuclear Medicine|2024Cited by 18